IRIS
BARGAGLI, ELENA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 22.961
EU - Europa 22.901
AS - Asia 10.546
SA - Sud America 2.147
AF - Africa 286
OC - Oceania 45
Continente sconosciuto - Info sul continente non disponibili 13
AN - Antartide 1
Totale 58.900
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 22.540
RU - Federazione Russa 5.247
IT - Italia 4.909
SG - Singapore 3.645
GB - Regno Unito 3.583
CN - Cina 3.308
IE - Irlanda 3.003
BR - Brasile 1.829
SE - Svezia 1.385
DE - Germania 1.275
HK - Hong Kong 1.060
FR - Francia 978
UA - Ucraina 792
FI - Finlandia 725
VN - Vietnam 655
KR - Corea 560
IN - India 401
CA - Canada 251
ES - Italia 229
NL - Olanda 179
JP - Giappone 147
BD - Bangladesh 121
PL - Polonia 120
TR - Turchia 113
CZ - Repubblica Ceca 111
MX - Messico 110
AR - Argentina 102
AT - Austria 92
CI - Costa d'Avorio 90
ZA - Sudafrica 78
IQ - Iraq 74
EC - Ecuador 59
IR - Iran 53
PK - Pakistan 49
BE - Belgio 45
UZ - Uzbekistan 44
MA - Marocco 39
SA - Arabia Saudita 39
ID - Indonesia 38
AU - Australia 34
AE - Emirati Arabi Uniti 31
CO - Colombia 29
VE - Venezuela 29
LT - Lituania 27
CH - Svizzera 26
CL - Cile 26
PH - Filippine 26
PE - Perù 23
PT - Portogallo 23
PY - Paraguay 22
EG - Egitto 21
JO - Giordania 21
IL - Israele 20
AZ - Azerbaigian 18
RO - Romania 18
DK - Danimarca 16
JM - Giamaica 16
KZ - Kazakistan 16
BG - Bulgaria 14
GR - Grecia 14
EE - Estonia 12
KG - Kirghizistan 12
UY - Uruguay 12
KE - Kenya 11
LV - Lettonia 11
BO - Bolivia 10
LB - Libano 10
DZ - Algeria 9
EU - Europa 9
LK - Sri Lanka 9
NG - Nigeria 9
TN - Tunisia 9
AL - Albania 8
ET - Etiopia 8
GE - Georgia 8
HU - Ungheria 8
PA - Panama 8
LA - Repubblica Popolare Democratica del Laos 7
MK - Macedonia 7
NO - Norvegia 7
NZ - Nuova Zelanda 7
TT - Trinidad e Tobago 7
AM - Armenia 6
CY - Cipro 6
DO - Repubblica Dominicana 6
LU - Lussemburgo 6
MY - Malesia 6
OM - Oman 6
RS - Serbia 6
BB - Barbados 5
BY - Bielorussia 5
CR - Costa Rica 5
GY - Guiana 5
NP - Nepal 5
SN - Senegal 5
TH - Thailandia 5
TW - Taiwan 5
HN - Honduras 4
IS - Islanda 4
MD - Moldavia 4
Totale 58.840
Salva come PNG Salva come JPEG
Città #
Dallas 4.507
Southend 3.037
Dublin 2.963
Singapore 2.309
Fairfield 2.071
Ashburn 1.779
Moscow 1.539
Chandler 1.436
Santa Clara 1.328
Hong Kong 1.026
Beijing 904
Woodbridge 879
Siena 820
Houston 762
Seattle 758
Wilmington 697
Hefei 642
Cambridge 629
Jacksonville 587
Seoul 532
Munich 486
Princeton 475
Milan 449
Helsinki 414
Ann Arbor 405
Los Angeles 397
New York 392
Lastra a Signa 349
Florence 316
Rome 205
Dong Ket 184
Nanjing 178
São Paulo 176
Ho Chi Minh City 166
Boardman 161
Buffalo 154
San Diego 153
Shanghai 152
The Dalles 144
Chicago 140
Dearborn 138
Bengaluru 135
Council Bluffs 130
London 127
San Mateo 127
Turku 123
Málaga 121
Redondo Beach 116
Tokyo 111
Fremont 100
Warsaw 98
Nuremberg 96
Hanoi 94
Abidjan 89
Lappeenranta 88
Düsseldorf 82
Lauterbourg 79
Nanchang 75
Brooklyn 70
Brno 67
Portsmouth 67
Stockholm 67
Montreal 62
Frankfurt am Main 61
Denver 57
Phoenix 57
Rio de Janeiro 57
Johannesburg 56
Washington 56
Menlo Park 55
Toronto 54
Atlanta 53
Guangzhou 52
Shenyang 52
Vienna 51
Ottawa 50
Chennai 49
San Francisco 47
Columbus 45
Poplar 45
Changsha 44
Brussels 42
Catania 41
Gavirate 41
Naples 41
Boston 40
Hangzhou 39
Norwalk 39
Belo Horizonte 38
Izmir 38
Mexico City 38
Olomouc 37
Orem 36
Tashkent 36
Dhaka 35
Manchester 35
Amsterdam 34
Zhengzhou 34
Hebei 33
Jinan 33
Totale 38.614
Salva come PNG Salva come JPEG
Nome #
La chitotriosidasi: un sensibile biomarker di sarcoidosi 1.025
ACE2 gene variants may underlie interindividual variability and susceptibility to COVID-19 in the Italian population 545
A first update on mapping the human genetic architecture of COVID-19 539
Association of toll-like receptor 7 variants with life-threatening COVID-19 disease in males: Findings from a nested case-control study 455
Towards a functional proteomics approach to the comprehension of idiopathic pulmonary fibrosis, sarcoidosis, systemic sclerosis and pulmonary Langerhans cell histiocytosis 355
Cytokine modulators in the treatment of sarcoidosis 348
Genetic mechanisms of critical illness in COVID-19 332
Antirheumatic agents in covid-19: is IL-6 the right target? 330
The polymorphism L412F in TLR3 inhibits autophagy and is a marker of severe COVID-19 in males 328
An explainable model of host genetic interactions linked to COVID-19 severity 324
Chitotriosidase: a biomarker of activity and severity in patients with sarcoidosis 317
Alveolar concentration of nitric oxide as a prognostic biomarker in idiopathic pulmonary fibrosis 309
A system biology study of BALF from patients affected by idiopathic pulmonary fibrosis (IPF) and healthy controls 305
Peripheral biomarkers' panel for severe COVID-19 patients 291
Employing a systematic approach to biobanking and analyzing clinical and genetic data for advancing COVID-19 research 286
Colonizzazione e trapianto di polmone: il possibile ruolo dei colonizzanti multiresistenti sugli eventi infettivi in uno studio pilota osservazionale-retrospettivo 282
Bronchoalveolar lavage proteomic analysis in pulmonary fibrosis associated with systemic sclerosis: S100A6 and 14-3-3ε as potential biomarkers 282
Pathogen-sugar interactions revealed by universal saturation transfer analysis 269
Chitotriosidase and soluble IL-2 receptor: comparison of two markers of sarcoidosis severity 266
Mapping the human genetic architecture of COVID-19 262
Accuracy of power Doppler ultrasonography in the diagnosis and monitoring of idiopathic inflammatory myopathies 260
Antithrombin III as predictive indicator of survival in IPF patients treated with Nintedanib: a preliminary study 260
Prognostic Biomarkers of Sarcoidosis: A Comparative Study of Serum Chitotriosidase, ACE, Lysozyme, and KL-6 259
Common, low-frequency, rare, and ultra-rare coding variants contribute to COVID-19 severity 258
POS0871 diagnostic accuracy og power doppler ultrasonography for the diagnosis of idiopathic inflammmatory myopathies 257
Long Covid: analisi di casistica in follow-up a seguito di successive ondate epidemiche 255
Exhaled nitric oxide in interstitial lung diseases 252
Harnessing the role of HDAC6 in Idiopathic Pulmonary Fibrosis: design, synthesis, structural analysis, and biological evaluation of potent inhibitors 250
Elevated level of Galectin-1 in bronchoalveolar lavage of patients with idiopathic pulmonary fibrosis 248
Idiopathic pulmonary fibrosis a rare disease with severe bone fragility 247
Gorham-Stout disease management during pregnancy 247
Serial KL-6 analysis in patients with idiopathic pulmonary fibrosis treated with nintedanib 246
Shorter androgen receptor polyQ alleles protect against life-threatening COVID-19 disease in European males 245
Increased Risk of Atherosclerosis in Patients with Sarcoidosis 244
Proteome Characterization of BALF Extracellular Vesicles in Idiopathic Pulmonary Fibrosis: Unveiling Undercover Molecular Pathways 243
Airway-Centered Pleuroparenchymal Fibroelastosis Associated with Non-Necrotizing Granulomas: A Rare New Entity 241
Familial pulmonary fibrosis: Clinical and radiological characteristics and progression analysis in different high resolution-CT patterns 240
Evaluation of multiple-flows exhaled nitric oxide in idiopathic and non-idiopathic interstitial lung disease 240
The effect of cigarette smoking on bronchoalveolar lavage protein profiles from patients with different interstitial lung diseases 238
Diagnosis of idiopathic pulmonary fibrosis by virtual means using “IPFdatabase”- a new software 236
Adiponectin and leptin levels in idiopathic pulmonary fibrosis: A new method for BAL and serum assessment 232
Rare variants in Toll-like receptor 7 results in functional impairment and downregulation of cytokine-mediated signaling in COVID-19 patients 232
Analysis of macrophage migration inhibitory factor (MIF) in patients with idiopathic pulmonary fibrosis 231
Combined sarcoidosis and idiopathic pulmonary fibrosis (CSIPF): A novel disease phenotype? 231
Mortality on the Waiting List for Lung Transplantation in Patients with Idiopathic Pulmonary Fibrosis: A Single-Centre Experience 230
Higher blood eosinophil levels after omalizumab treatment may be associated with poorer asthma outcomes 228
A Comprehensive Evaluation of Mepolizumab Effectiveness in a Real-Life Setting 227
A genome-wide association study reveals evidence of association with sarcoidosis at 6p12.1 226
Pleuroparenchymal fibroelastosis (PPFE) associated with giant cell arteritis: A coincidence or a novel phenotype? 226
Carriers of ADAMTS13 Rare Variants Are at High Risk of Life-Threatening COVID-19 225
Pulmonary hypertension in idiopathic pulmonary fibrosis: prevalence and clinical progress 225
Omalizumab treatment in Samter's triad: case series and review of the literature 225
Analysis of trace elements in bronchoalveolar lavage of patients with diffuse lung diseases 223
Serum chitotriosidase levels in patients with allergic and non-allergic asthma 221
Serum amyloid A in patients with idiopathic pulmonary fibrosis 221
Rituximab Therapy in Interstitial Lung Disease associated with Rheumatoid Arthritis 219
Carbonylated proteins in bronchoalveolar lavage of patients with sarcoidosis, pulmonary fibrosis associated with systemic sclerosis and idiopathic pulmonary fibrosis 218
Diagnosis of Hypersensitivity Pneumonitis in Adults: An Official ATS/JRS/ALAT Clinical Practice Guideline 218
Exhaled carbon monoxide in sarcoidosis 217
Calgranulin B (S100A9/MRP14): a Key molecule in idiopathic pulmonary fibrosis? 217
Prognostic bioindicators in severe COVID-19 patients 217
SARS-CoV-2 susceptibility and COVID-19 disease severity are associated with genetic variants affecting gene expression in a variety of tissues 216
Alveolar nitric oxide is related to periostin levels in idiopathic pulmonary fibrosis 215
Ceruloplasmin and oxidative stress in severe eosinophilic asthma patients treated with Mepolizumab and Benralizumab 214
Adaptive immune system in pulmonary sarcoidosis - comparison of peripheral and alveolar biomarkers 214
COVID-19 pneumonia in a large cohort of patients treated with biological and targeted synthetic antirheumatic drugs 213
Serial KL-6 measurements in COVID-19 patients 212
Calgranulin B (S100A9) levels in bronchoalveolar lavage fluid of patients with interstitial lung diseases. 211
Cytokine profile and proteome analysis in bronchoalveolar lavage of patients with sarcoidosis, pulmonary fibrosis associated with systemic sclerosis and idiopathic pulmonary fibrosis 210
AB0611 Neutrophil extracellular traps and interstitial lung disease in ANCA-associated vasculitis: a scoping review 209
Efficacy of pirfenidone for idiopathic pulmonary fibrosis: An Italian real life study 209
Fibrotic lung toxicity induced by cytotoxic drugs, radiation and immunotherapy in patients treated for lung cancer 208
Chitotriosidase activity in patients with interstitial lung disesaes 207
Serum levels of chitotriosidase as a marker of disease activity and clinical stage in sarcoidosis. 206
Asthma control in severe asthmatics under treatment with omalizumab: A cross-sectional observational study in Italy 205
BAL biomarkers’ panel for differential diagnosis of interstitial lung diseases 204
A real-life experience with ImmunoCAP ISAC: the advantages of a new diagnostic method 204
Galactin-1, 3 and 9: Potential biomarkers in idiopathic pulmonary fibrosis and other interstitial lung diseases 204
Severe COVID-19 in hospitalized carriers of single CFTR pathogenic variants 204
NK and NKT-like cells in granulomatous and fibrotic lung diseases 203
Chromosome 5 inversion in two siblings, one with Klinefelter syndrome and systemic sclerosis, the other with rheumatoid arthritis 202
Alveolar nitric oxide as a biomarker of COVID-19 lung sequelae: A pivotal study 202
A Multidisciplinary Approach to Improve the Management of Immune-Checkpoint Inhibitor-Related Pneumonitis 201
The analysis of tryptase in serum of sarcoidosis patients 201
Trace metals in fluids lining the respiratory system of patients with idiopathic pulmonary fibrosis and diffuse lung diseases 201
Serum KL-6 concentrations as a novel biomarker of severe COVID-19 201
A functional proteomics approach to the comprehension of sarcoidosis 200
Pirfenidone in chronic lung allograft dysfunction: a single cohort study 200
Bronchoalveolar lavage and serum KL-6 concentrations in chronic hypersensitivity pneumonitis: correlations with radiological and immunological features 200
Analysis of carbonylated proteins in BAL of patients with diffuse lung diseases 199
Quality of life, anxiety and depression in Sarcoidosis 198
Gain- and Loss-of-Function CFTR Alleles Are Associated with COVID-19 Clinical Outcomes 197
BAL and serum multiplex lipid profiling in idiopathic pulmonary fibrosis and fibrotic hypersensitivity pneumonitis 195
Assessment of cardiac involvement in sarcoidosis by echocardiography 193
Pirfenidone in idiopathic pulmonary fibrosis: real-life experience in the referral centre of Siena 193
Phenotypes of organ involvement in sarcoidosis 193
Proteome analysis of bronchoalveolar lavage in lung diseases 192
Incidence and risk factors for respiratory tract bacterial colonization and infection in lung transplant recipients 192
Regulatory T Cells in Severe Persistent Asthma in the Era of Monoclonal Antibodies Target Therapies 191
C9orf72 intermediate repeats confer genetic risk for severe covid-19 pneumonia independently of age 191
Totale 25.035
Salva come PNG Salva come JPEG
Categoria #
all - tutte 201.808
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 201.808
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20213.460 0 0 0 0 0 656 317 663 496 375 422 531
2021/20224.509 351 594 368 307 224 157 199 211 186 526 485 901
2022/20235.759 426 595 721 693 420 1.048 359 491 450 203 213 140
2023/20245.542 218 138 518 273 294 1.285 1.652 226 62 180 179 517
2024/202512.190 715 525 1.293 672 1.401 661 611 736 943 618 1.276 2.739
2025/202618.556 2.064 3.934 3.602 3.402 5.313 241 0 0 0 0 0 0
Totale 60.281